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Katarzyna Kurnicka, MD, PHD,* Olga Dzikowska-Diduch, MD,*
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Warsaw, PolandOBJECTIVES The goal of the study was to evaluate the prognostic value of echocardiographic
indices of right ventricular dysfunction (RVD) for prediction of pulmonary embolism–related 30-day mor-
tality or need for rescue thrombolysis in initially normotensive patients with acute pulmonary embolism
(APE).
BACKGROUND There is no generally accepted echocardiographic deﬁnition of RVD used for prog-
nosis in APE.
METHODS We studied the prognostic value of a set of echocardiographic parameters in 411 consec-
utive patients (234 women, age 64  18 years) with APE hemodynamically stable at admission.
RESULTS Thirty-day APE-related mortality was 3% (14 patients), all-cause mortality was 5% (21 pa-
tients). Nine patients received thrombolysis as a result of hemodynamic deterioration, and 7 of them sur-
vived. The clinical endpoint (CE), which included APE-related death or thrombolysis, occurred in 21
patients. At univariable Cox analysis, the hazard ratio (HR) for CE of the right ventricular (RV)/left ventric-
ular (LV) ratio was 7.3 (95% conﬁdence interval [CI]: 2.0 to 27.3; p ¼ 0.003). However, multivariable anal-
ysis showed that tricuspid annulus plane systolic excursion (TAPSE) was the only independent predictor
(HR: 0.64, 95% CI: 0.54 to 0.7; p < 0.0001). Moreover, the area under the curve (AUC) in receiver-operating
characteristic analysis for TAPSE (0.91, 95% CI: 0.856 to 0.935; p ¼ 0.0001) in CE prediction was higher
(p < 0.001) than AUC of RV/LV ratio (0.638, 95% CI: 0.589 to 0.686; p ¼ 0.001). TAPSE #15 mm had a
HR of 27.9 (95% CI: 6.2 to 124.6; p < 0.0001) and a positive predictive value (PPV) of 20.9% for CE
with a 99% negative predictive value (NPV), whereas TAPSE #20 mm had a PPV of 9.2 with a 100%
NPV. RV/LV ratios of >0.9 and >1.0 had a PPV of 13.2% and 14.4% and a NPV of 97% and 94.3%,
respectively.
CONCLUSIONS TAPSE is preferable to the RV/LV ratio for risk stratiﬁcation in initially normotensive
patients with APE. TAPSE #15 mm identiﬁes patients with an increased risk of 30-day APE-related mor-
tality, whereas TAPSE >20 mm can be used for identiﬁcation of a very low-risk group. (J Am Coll Cardiol
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AA B B R E V I A T I O N S
A N D A C R O N YM S
APE = acute pulmonary
embolism
AUC = area under the curv
CE = clinical endpoint
CI = conﬁdence interval
HR = hazard ratio
LV = left ventricle/ventricu
NPV = negative predictive
PPV = positive predictive v
ROC = receiver-operating
characteristic
RV = right ventricle/ventric
RVD = right ventricular
dysfunction
TAPSE = tricuspid annular
systolic plane excursion
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554lthough short-term prognosis in acute pul- Philips iE33 or Philips HD11XE system (Philips
monary embolism (APE) predominantly
depends on the patient’s hemodynamic
status and comorbidities (1,2), right ven-
tricular dysfunction (RVD) and injury also have a
signiﬁcant prognostic value in hemodynamically
stable APE patients (3–5). Right ventricular (RV)
enlargement, detected at echocardiography in ap-
proximately 30% of normotensive patients with APE
(6–8), is regarded as a predictor of poor clinical
outcome, even in initially stable patients. American
Heart Association guidelines on submassive pulmo-
nary embolism arbitrarily proposed that RVD should
be diagnosed when the right ventricular to left ven-
tricular (LV) end-diastolic ratio (RV/LV) measured
by echocardiography or tomography exceeds 0.9 (1).
However, a wide range of criteria for RVD one
lar
value
alue
ularechocardiography were used in different
studies (1,2,9,10). Moreover, to our
knowledge, no direct comparison of echo-
cardiographic criteria for short-term risk
prognosis in APE is available. Therefore,
we analyzed the prognostic value of clini-
cally used echocardiographic parameters of
RVD for prediction of pulmonary embo-
lism (PE)-related 30-day mortality or need
for rescue thrombolysis in initially normo-
tensive patients with APE, and compared
their prognostic value with the value of
RV/LV ratio, the most frequently used
RVD parameter.
MATER IALS AND METHODS
Patients and management of APE. The
study group comprised 411 consecutive
patients with symptomatic APE, hemo-dynamically stable at admission, who were diag-
nosed and treated in our department. PE was
conﬁrmed by contrast-enhanced multidetector
computed tomography when thromboemboli were
visualized in an at least segmental pulmonary artery.
On admission, all patients had a systemic systolic
blood pressure of at least 90 mm Hg and showed no
signs of peripheral hypoperfusion. APE was diag-
nosed when symptoms of PE had been present for
no longer than 14 days before the diagnosis. Pa-
tients with diagnosed chronic thromboembolic hy-
pertension and participants in therapeutic clinical
trials were not included in this study.
Echocardiography. Routine transthoracic echocar-
diography for the assessment of RVD was per-
formed and interpreted according to a standardized
protocol by an experienced physician using aMedical Systems, Best, the Netherlands), as soon
as possible after admission. The examinations were
digitally recorded. RV and LV diastolic diameters
were measured in the parasternal long-axis view. In
the apical 4-chamber view, LV and RV diastolic
diameters were measured at the level of the mitral
and tricuspid valve tips during late diastole (deﬁned
by the electrocardiogram R-wave), and the presence
of McConnell’s sign was assessed (11,12). Left
ventricular ejection fraction was assessed using
Simpson’s method (13). Tricuspid annular plane
systolic excursion (TAPSE) was assessed in the
M-mode presentation by placing a cursor in the
tricuspid annulus and measuring the amount of
longitudinal motion of the annulus at peak systole
(12). Tricuspid valve regurgitation was qualitatively
assessed by color Doppler, and peak gradient was
calculated using a simpliﬁed Bernoulli’s formula,
using tricuspid regurgitant ﬂow peak velocity. In
the short parasternal axis, ﬂattening of the inter-
ventricular septum was assessed qualitatively, and
acceleration time of pulmonary ejection and peak
pulmonary valve systolic velocity were measured in
the RV outﬂow tract, proximal to the pulmonary
valve. The examination was completed by mea-
surement of the inferior vena cava at late
expiration.
Echocardiography was performed immediately on
admission in 193 patients, within 24 h in 159 pa-
tients, and between 24 and 72 h after admission in
59 patients.
Submassive (intermediate-risk) APE was diag-
nosed when RVD was diagnosed at echocardiog-
raphy, whereas the remaining subjects formed the
low-risk group. Pre-deﬁned RVD was diagnosed
when echocardiography showed: 1) RV free wall
hypokinesis and RV/LV >0.9 in the 4-chamber
apical view; and/or 2) an elevated tricuspid valve
pressure gradient exceeding 30 mm Hg with a
shortened acceleration time of pulmonary ejection
below 80 ms.
The clinical endpoint (CE) of the study was
deﬁned as a combination of 30-day APE-related
mortality and/or rescue thrombolysis in patients
with hemodynamic deterioration, which was
deﬁned by occurrence of at least 1 of the following:
1) the need for cardiopulmonary resuscitation;
2) systolic blood pressure below 90 mm Hg for at
least 15 min, with signs of end-organ hypo-
perfusion; or 3) the need for intravenous catechol-
amines in vasopressor doses.
This observational study was approved by the
local ethics committee.
Table 1. Clinical Characteristics of Studied Patients With APE
All Patients
(N [ 411)
APE-Related
Mortality or
Thrombolysis
(n [ 21) p Value
Remaining
Patients
(n [ 390)
Female/male 234/177 14/7 0.48 220/170
Age, yrs 64  18 70  22 0.13 64  18
HR 1 beat/s 87  19 102  24 0.0002 87  18
Systemic blood
pressure, mm Hg
128  20 120  24 0.04 129  20
Comorbidities (COPD,
CHF, neoplasm)
142 (35) 9 (43) 0.56 133 (34)
Thrombolysis, % 2 43 d 0
Troponin, ng/ml 0.03 (0.00–5.58) 0.28 (0.00–0.98) 0.014 0.03 (0.00–0.58)
Troponin positive 224 (54) 17 (81) 0.02 207 (53)
NT-proBNP, pg/ml 685 (20–29,071) 4,872 (2,043–25,000) 0.0003 649 (20–29,071)
Values are n, mean  SD, n (%), or median (maximum–minimum range). Comorbidities were deﬁned as the
presence of 1 of chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), or history of
cancer. Troponins were considered positive at levels >0.01 ng/ml.
APE ¼ acute pulmonary embolism; HR ¼ heart rate; NT-proBNP ¼ N-terminal pro–B-type natriuretic
peptide.
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555Statistical analysis. This is a prospective observa-
tional cohort study. Data characterized by a normal
distribution are expressed as means followed by SD.
Parameters without such a distribution are expressed
as medians with maximum minimum ranges. Stu-
dent t test or Mann-Whitney U test was used for
comparisons between 2 groups, whereas compari-
sons between more than 2 groups were performed
by analysis of variance or Kruskal-Wallis tests.
The chi-square test was used to compare discrete
variables (with Yates’ correction when needed).
Receiver-operating characteristic (ROC) curves
were analyzed to assess the optimal cutoff values of
echocardiographic parameters for the CE.
Two different cutoff values of echocardiographic
parameters were deﬁned: 1 that identiﬁes patients
with a good prognosis (i.e., with a high negative
predictive value [NPV] for the CE), and 1 that
identiﬁes subjects at risk (i.e., with a high positive
predictive value [PPV] for the CE).
Sensitivity, speciﬁcity, PPV, and NPV were
calculated for the chosen cutoff value. Kaplan-Meier
analysis was used to investigate cumulative 30-day
survival free of the CE. The impact of echocardio-
graphic parameters on CE was evaluated using uni-
variable Cox proportional-hazards regression.
Forward stepwise selection with a 0.1 level for staying
in the model was used to identify signiﬁcant pre-
dictors in multivariable analysis. Areas under the
ROC curves were compared pairwise according to
DeLong et al. (14). All tests were 2-sided. Data were
considered signiﬁcant at p < 0.05. The STATIS-
TICA data analysis software system (2011, version
10, StatSoft, Tulsa, Oklahoma) and MedCalc soft-
ware (version 11.0.0.0, Ostend, Belgium) were used
for statistical calculations. The study protocol was
approved by the local ethics committee.
RESULTS
Patient characteristics and clinical course. The study
included 411 consecutive patients with APE (234
women and 177 men, age 64  18 years). There
were 241 patients (58.6%) with submassive APE,
and 170 patients (41.4%) with low-risk APE (1)
(Table 1). All patients were initially given anti-
coagulation agents with body mass–adjusted low-
molecular-weight heparin or activated partial
thromboplastin time–adjusted unfractionated hep-
arin intravenous infusion. Urgent thrombolysis was
performed in 9 (3.7%) of 241 patients from the
submassive group, 7 of them survived. Clinical
deterioration was observed in all these cases, and the
time from starting anticoagulation to thrombolysisranged from 1 h to 168 h (median 15 h). No pa-
tients from the low-risk group received thrombol-
ysis. Vitamin K antagonists were administered to
the majority of patients following hemodynamic
stabilization, with a target international normalized
ratio of 2 to 3.
The 30-day APE-related mortality was 3%
(n ¼ 14), whereas all-cause mortality was 5%
(n ¼ 21). The 7 non–APE-related deaths were due
to cancer (2 cases), advanced congestive systolic
heart failure (2 cases), severe aortic stenosis with
severe LV dysfunction, gastrointestinal bleeding,
and bilateral pneumonia. Nine initially stable pa-
tients received thrombolysis due to clinical deterio-
ration, 7 of them survived. Finally, the CE, which
included APE-related death or thrombolysis, was
observed in 21 patients.
Patients who experienced CE presented with
increased heart rate, elevated plasma N-terminal
pro–B-type natriuretic peptide (NT-proBNP), and
more frequent biochemical signs of myocardial
injury than patients with favorable clinical course
(Table 1).
Echocardiography. Table 2 includes echocardio-
graphic data of studied patients. Almost all echo-
cardiographic parameters assessing RV morphology
and function indicated more signiﬁcant RV
impairment in patients with CE than in subjects
with an uncomplicated clinical course. Only RVD,
both in the long parasternal axis and apical
4-chamber apical view, and RV/LV ratio measured
in the long-axis parasternal view did not differ
Table 2. Echocardiographic Characteristics of Studied Patients With APE
All Patients
(N [ 411)
APE-Related Mortality
or Thrombolysis
(n [ 21) p Value
Remaining Patients
(n [ 390)
RVlax, mm 27 (17–58) 29 (17–39) 0.97 27 (17–58)
LVlax, mm 43 (13–66) 40 (29–51) <0.01 43 (13–66)
RV/LVlax 0.63 (0.32–2.00) 0.69 (0.45–1.03) 0.13 0.62 (0.32–2.00)
RV4C, mm 37 (20–60) 39 (20–60) 0.18 36 (21–59)
LV4C, mm 42 (22–67) 39 (22–54) 0.01 42 (25–67)
RV/LV4C 0.88 (0.46–2.00) 1.08 (0.48–2.00) 0.003 0.87 (0.46–1.93)
PVvel, cm/s 0.8 (0.4–1.7) 0.6 (0.4–1.1) <0.001 0.8 (0.4–1.7)
AcT, ms 88 (30–170) 70 (30–111) 0.002 90 (34–170)
TR, moderate/severe, % 22 (5) 4 (19) 0.02 18 (5)
TRPG, mm Hg 31 (7–100) 45 (15–100) 0.03 30 (7–88)
TAPSE, mm 21 (6–34) 12 (6–20) <0.0001 21 (6–34)
IVS ﬂattening, % 102 (25) 10 (48) 0.01 92 (24)
McConnell sign, % 77 (18) 9 (43%) <0.01 68 (17)
LVEF, % 60 (15–70) 55 (15–68) <0.01 60 (15–70)
IVC, mm 15 (5–35) 18 (10–26) 0.03 15 (5–35)
Values are median (maximum–minimum range) or n (%).
AcT ¼ pulmonary ejection acceleration time; APE ¼ acute pulmonary embolism; CI ¼ conﬁdence interval; HR ¼ hazard ratio; IVC ¼ inferior vena cava;
IVS ¼ interventricular septum; LV4C ¼ left ventricular dimension in apical four chamber view; LVEF ¼ left ventricular ejection fraction; LVlax ¼ left ventricular
dimension in the parasternal long-axis; PVvel ¼ pulmonary valve peak systolic velocity; RV4C ¼ right ventricular dimension in apical four chamber view;
RVlax ¼ right ventricular dimension in the parasternal long-axis; TAPSE ¼ tricuspid annular plane systolic excursion; TR ¼ tricuspid valve regurgitation;
TRPG ¼ tricuspid valve peak gradient.
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556between groups. Interestingly, the CE group
presented with signiﬁcantly lower left ventricular
ejection fraction. We observed a correlation bet-
ween TAPSE and plasma NT-proBNP level
(r ¼ 0.661, p < 0.0001).
Hazard risk of echocardiographic predictors of CE in
univariable analysis. Univariable Cox proportional
hazards regression analysis showed that most of the
measured echocardiographic parameters signiﬁ-
cantly predicted clinical outcome (Table 3). RV/LV
ratio measured in the apical 4-chamber view showed
the highest hazard ratio (HR) for APE related
mortality or rescue thrombolysis (HR: 7.3, 95%
conﬁdence interval [CI]: 2.0 to 27.3; p ¼ 0.003).
Only RV dimension and RV/LV in the parasternal
long-axis view were not signiﬁcantly different be-
tween groups. However, multivariable analysis
showed that TAPSE (HR: 0.64, 95% CI: 0.54 to
0.7; p < 0.0001) was the only independent predictor
of 30-day PE-related mortality or thrombolysis.
ROC curve analysis. ROC analysis (Table 4) showed
that the area under the curve for TAPSE in the
prediction of clinical course was the highest (area
under the curve [AUC]: 0.91, 95% CI: 0.856 to
0.935; p ¼ 0.0001). Moreover, the AUC of
TAPSE was higher than the AUC of RV/LV ratio,
p < 0.001 (Fig. 1). We deﬁned 2 cutoff valuesof TAPSE. TAPSE #15 mm (17% of studied
patients) showed a PPV of 20.9% for CE with a
99% NPV, whereas TAPSE #20 mm had a PPV
of 9.2 with a 100% NPV. Therefore, all patients
with TAPSE >20 mm (53% of studied patients)
formed a low-risk group with good prognosis
(Fig. 2), whereas TAPSE #15 mm identiﬁed
among initially normotensive patients was associ-
ated with a 20.9% risk of APE-related death or
rescue thrombolysis (Fig. 3). The previously pro-
posed cutoff values of the RV/LV ratio of >0.9 and
>1.0 had a PPV of 13.2% and 14.4% and NPV of
97% and 94.3%, respectively, for CE. McConnell’s
sign had a PPV of 38% and NPV of 94% for CE.
TAPSE and RV/LV ratio for outcome prediction in
submassive PE. Most of the CEs occurred in pa-
tients with submassive PE (19 of 241 patients),
whereas only 2 of 170 patients without RVD
experienced CE. ROC analysis showed signiﬁcantly
higher AUC for TAPSE when compared with RV/
LV ratio 0.87 (95% CI: 0.82 to 0.91) versus 0.60
(95% CI: 0.53 to 0.67), p < 0.001. Cox
proportional-hazards regression analysis showed
that both TAPSE and the RV/LV ratio signiﬁ-
cantly predicted clinical outcome in submassive PE.
HR for TAPSE was 0.67 (95% CI: 0.56 to 0.80),
p ¼ 0.00001, and for RV/LV was 4.40 (95%
Table 3. Univariable Predictors of APE-Related Mortality or
Rescue Thrombolysis in 411 Initially Normotensive Patients
HR 95% CI p Value
RVlax 0.999 0.928–1.075 0.98
RV/LVlax 3.38 0.74–15.51 0.12
RV4C 1.04 0.98–1.10 0.17
RV/LV4C 7.3 2.0–27.3 0.003
IVC 1.09 1.01–1.18 0.03
PVvel 0.003 0.0001–0.0793 0.0005
AcT 0.97 0.95–0.99 0.002
TRPG 1.030 1.003–1.058 0.03
TAPSE 0.71 0.62–0.81 <0.0001
TAPSE #15 mm 27.9 6.2–124.6 <0.0001
IVS ﬂattening 3.1 1.3–7.4 0.01
McConnell sign 3.6 1.5–8.7 0.004
TR moderate/severe 4.7 1.6–14.3 <0.01
LVEF, % 0.96 0.93–0.99 0.01
Abbreviations as in Table 2.
Table 4. ROC Analysis of Signiﬁcant Echocardiographic Parameters
in the Prediction of a Complicated Clinical Course
AUC 95% CI p Value Cutoff Point PPV NPV
AcT 0.699 0.652–0.743 0.0001 <90 ms 8.3 98.0
IVC 0.666 0.616–0.713 0.01 >15 mm 8.0 97.1
LVEF 0.688 0.639–0.733 0.0003 <60% 12.8 97.0
PVvel 0.741 0.691–0.787 0.0001 <0.70 m/s 13.0 97.7
RV/LV4C 0.638 0.589–0.686 0.04 >1.0 13.2 97.0
>0.9 14.4 94.3
TAPSE 0.901 0.856–0.935 0.0001 #15 mm 20.9 99.0
#20 mm 9.2 100.0
TRPG 0.636 0.585–0.685 0.07 >42 mm Hg 9.5 97.5
AUC ¼ area under the curve; ROC ¼ receiver-operating characteristic; other abbreviations as
in Table 2.
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557CI: 1.07 to 18.0), p < 0.04. However, TAPSE
<16 mm showed high HR in the outcome predic-
tion (HR: 14.48, 95% CI: 3.12 to 67.0; p < 0.001).
Moreover, TAPSE <16 mm for the prediction of
CE in submassive PE showed a PPV of 22.5% (95%
CI: 9.6% to 35.4%), whereas RV/LV >1 had a PPV
of 13.1% (95% CI: 5.9% to 20.3%). NPV of
TAPSE >20 reached 100% (95% CI: 100% to
100%), whereas NPV of RV/LV >1 ratio had NPV
of 95% (95% CI: 91.1% to 98.9%).Figure 1. ROC of TAPSE and RV/LV4C for Clinical Endpoint in
Normotensive Patients
Receiver-operating characteristic (ROC) analysis of tricuspid annular plane
systolic excursion (TAPSE) and right to left ventricular diastolic dimensions ratio
measured in 4-chamber view (RV/LV4C) for 30-day pulmonary embolism–
related mortality and rescue thrombolysis in normotensive patients.
AUC ¼ area under the curve.DISCUSS ION
Normotensive patients with APE include, not only
subjects with benign clinical course, but also patients
with an increased risk of APE-related mortality.
Although the former may be candidates for a short
hospital stay or even ambulatory treatment, the
latter require close monitoring, and in some cases,
even more aggressive therapy, including thrombol-
ysis. However, precise short-term stratiﬁcation of
normotensive patients with APE is still a matter of
ongoing discussion (15–17). The mortality rate re-
ported in normotensive APE patients with RVD
diagnosed according to different criteria varied
markedly from 4.3% up to 16.4% (8,18–20).
Recently, an increased RV to LV end-diastolic ratio
measured by echocardiography or tomography was
proposed as a potential indicator of poor outcome
(1,9,21). However, although right ventricular dys-
function has been included in the risk stratiﬁcationstrategy, there is no generally accepted and validated
deﬁnition of RVD (2,22).
We tried to deﬁne the optimal, easily measured
echocardiographic criteria of RVD for risk stratiﬁ-
cation and compare them with the prognostic value
of the previously proposed RV/LV ratio of 0.9 or
1.0. Four hundred eleven consecutive patients with
Figure 2. Individual TAPSE Values in Initially Normotensive Patients
According to Clinical Course
Distribution of individual tricuspid annular plane systolic excursion (TAPSE)
values in initially normotensive patients according to clinical course. (A) Un-
complicated clinical course (n ¼ 390), (B) patients with acute pulmonary em-
bolism (APE)-related mortality or thrombolysis (n ¼ 21).
Figure 3.
411 Initia
Kaplan-M
patients w
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All patients underwent echocardiography as a part
of routine assessment. All patients initially were
given anticoagulation agents, and thrombolysis was
used only in case of deterioration. Thirty-day APE-
related mortality or need for rescue thrombolysis
due to hemodynamic deterioration were the end-
points of the current study. Fourteen patients diedKaplan-Meier Survival Analysis According to TAPSE in
lly Normotensive Patients With APE
eier survival analysis according to TAPSE in 411 initially normotensive
ith APE. CE ¼ clinical endpoint; other abbreviations as in Figure 2.as a result of PE, including 2 who received rescue
thrombolysis (APE-related mortality 3.4%). The 12
remaining nonsurvivors did not receive thrombolytic
treatment because of high bleeding risk, as assessed
by the managing physician. Importantly, 7 of 9
patients who received urgent thrombolysis survived.
Therefore, the CE of our study, comprising APE-
related mortality and rescue thrombolysis, was pre-
sent in 21 cases.
Various echocardiographic parameters were
found to be signiﬁcant predictors of CE in uni-
variable analysis. However, in multivariable analysis,
only TAPSE was found to be a signiﬁcant predictor.
ROC analysis for CE prediction showed a high
AUC for TAPSE (AUC: 0.91, 95% CI: 0.856 to
0.935; p ¼ 0.0001). Importantly, the AUC for
TAPSE was signiﬁcantly higher than the AUC of
the RV/LV ratio or other echocardiographic pa-
rameters. Therefore, we found TAPSE to be the
most valuable predictor of clinical course among a
wide set of echocardiographic indices. Systolic
excursion of the lateral tricuspid annulus is an in-
dicator of longitudinal function of the RV. It is well
known that longitudinal myocardial shortening is a
signiﬁcant contributor to RV function, rather than
reduction in cavity diameter, as is the case for the
LV (12,23). TAPSE reﬂects global systolic RV
function, whereas the RV/LV ratio provides data on
RV morphology, and McConnell’s sign represents
only regional function abnormalities.
It should be underlined that TAPSE is a well-
known, easy to measure, and reproducible param-
eter that does not require sophisticated equipment
or prolonged image analysis (24), with a proven
prognostic value in congestive heart failure (25).
Decreased RV systolic function estimated by
TAPSE was found to be associated with increased
mortality in patients admitted for heart failure, and
is independent of other mortality risk factors in this
group of patients (26). Interestingly, in 50 patients
with APE, TAPSE reﬂected the severity of RVD
deﬁned by plasma BNP levelda signiﬁcant corre-
lation with BNP plasma and TAPSE was found
(r ¼ 0.634, p < 0.001) (27), and we observed a
similar correlation between TAPSE and plasma
NT-proBNP. Moreover, in a group of 37 consec-
utive patients with pulmonary hypertension, among
various echocardiographic parameters, TAPSE
exhibited the strongest correlation with cardiac
magnetic resonance–derived RV ejection fraction
(r ¼ 0.86, p < 0.001), and only TAPSE signiﬁ-
cantly predicted cardiac magnetic resonance–derived
RV ejection fraction in multiple regression analysis
(28). Using ROC analysis, we deﬁned 2 cutoff
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559values of TAPSE, including #15 mm, which
identiﬁed 17% of initially normotensive patients
at risk of a complicated clinical course. The PPV
for APE-related death or thrombolysis in this group
was 20.9%. Interestingly, a TAPSE of 16 mm was
recently deﬁned as a lower reference value of RV
function (12). Moreover, guidelines on pulmonary
arterial hypertension also proposed TAPSE as a
prognostic tool, and TAPSE #15 mm has been
regarded as an indicator of poor outcome (29).
The second TAPSE threshold (>20 mm) iden-
tiﬁed normotensive patients with favorable outcome
(53%). None of these patients experienced a
complicated clinical course. Interestingly, TAPSE
>20 mm has been reported to identify patients with
pulmonary arterial hypertension with a favorable
prognosis (29). Our results indicate that TAPSE is
superior to RV/LV ratio for 30 days prognosis also
in patients with submassive PE.
Clinical implications. Measurement of TAPSE may
help in the management of normotensive APE
patients. Patients with TAPSE >20 mm form
a group of approximately 50% of normotensive
patients with benign clinical course, free of
APE-related complications. If other factors are
considered, such as a lack of coexisting diseases,
inﬂuencing outcome and low bleeding risk, the
duration of their hospitalization may be very short.
On the other hand, patients with TAPSE #15 mm
should be at least closely monitored. Probably,
TAPSE #15 mm identiﬁes a group in whomthrombolysis may be considered, especially when
additional parameters such as elevated troponin
levels indicate increased risk.
Study limitations. This is a single-center observa-
tional study. Causes of death were not adjudicated.
Because of the limited number of CEs observed in
our study, the ability of stepwise multivariable
methods to select models from among 11 signiﬁcant
predictors in univariable analysis should be regarded
with caution. Therefore, our results should be vali-
dated in an external population with APE.
Although we tried to perform echocardiography as
soon as possible after admission, in some patients, it
was performed with some delay.CONCLUS IONS
Our data indicate that TAPSE is preferable to RV/
LV ratio for risk stratiﬁcation in initially normo-
tensive patients with APE. TAPSE #15 mm
identiﬁes patients with an increased risk of 30-day
APE-related mortality or rescue thrombolysis,
whereas TAPSE >20 mm can be used for identi-
ﬁcation of a very low-risk group, who may be can-
didates for a short hospital stay or even outpatient
treatment.
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